Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

Fougeroux, Cyrielle; Goksøyr, Louise; Idorn, Manja; Soroka, Vladislav; Myeni, Sebenzile K.; Dagil, Robert; Janitzek, Christoph M.; Soegaard, Max; Aves, Kara-Lee; Horsted, Emma Wenzel; Erdoğan, Sayit Mahmut; Gustavsson, Tobias; Dorosz, Jerzy; Clemmensen, Stine; Fredsgaard, Laurits; Thrane, Susan; Vidal-Calvo, Elena E.; Khalifé, Paul; Hulen, Thomas Morgan; Choudhary, Swati; Theisen, Michael; Singh, Susheel K.; Garcia-Senosiain, Asier; Oosten, Linda van; Pijlman, Gorben P.; Hierzberger, Bettina; Domeyer, Tanja; Nalewajek, Blanka W.; Strøbæk, Anette; Skrzypczak, Magdalena; Andersson, Laura F.; Buus, Søren; Stryhn, Anette; Christensen, Jan Pravsgaard; Dalebout, Tim J.; Iversen, Kasper; Harritshøj, Lene Holm; Mordmüller, Benjamin; Ullum, Henrik; Reinert, Line S.; Jongh, Willem A. de; Kikkert, Marjolein; Paludan, Søren R.; Theander, Thor G.; Nielsen, Morten A.; Salanti, Ali; Sander, Adam F.

doi:10.1038/s41467-020-20251-8

Cited by 105 publications

(114 citation statements)

References 69 publications

Supporting

Mentioning

108

Contrasting

Order By: Relevance

“…Furthermore, RBD was added with a binding protein (BiP) insect signal peptide at the Nterminus in addition to an EPEA (Glu-Pro-Glu-Ala) tag at the Cterminus. The proprietary peptide-binding Tag and a linker (GSGTAGGGSGS) were added to the N-terminus of the Acinetobacter phage AP205 coat protein (101).…”

Section: Rbd As Antigen For Sars-cov-2 Vaccinesmentioning

confidence: 99%

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants

et al. 2021

View full text Add to dashboard Cite

Coronavirus 19 Disease (COVID-19) originating in the province of Wuhan, China in 2019, is caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), whose infection in humans causes mild or severe clinical manifestations that mainly affect the respiratory system. So far, the COVID-19 has caused more than 2 million deaths worldwide. SARS-CoV-2 contains the Spike (S) glycoprotein on its surface, which is the main target for current vaccine development because antibodies directed against this protein can neutralize the infection. Companies and academic institutions have developed vaccines based on the S glycoprotein, as well as its antigenic domains and epitopes, which have been proven effective in generating neutralizing antibodies. However, the emergence of new SARS-CoV-2 variants could affect the effectiveness of vaccines. Here, we review the different types of vaccines designed and developed against SARS-CoV-2, placing emphasis on whether they are based on the complete S glycoprotein, its antigenic domains such as the receptor-binding domain (RBD) or short epitopes within the S glycoprotein. We also review and discuss the possible effectiveness of these vaccines against emerging SARS-CoV-2 variants.

show abstract

Section: Rbd As Antigen For Sars-cov-2 Vaccinesmentioning

confidence: 99%

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants

et al. 2021

View full text Add to dashboard Cite

show abstract

“…have developed so-called capsid-like particles (CLPs) that display the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Tested in mice, these particles seem to induce levels of neutralizing antibodies comparable to those found in patients that had recovered from COVID-19 [247]. Furthermore, when encapsulating viral mRNA, VLPs can also be used as a positive control for RT-qPCR detection of SARS-CoV-2 [248].…”

Section: Virus-like Particles (Vlps)mentioning

confidence: 84%

Use of Protamine in Nanopharmaceuticals—A Review

et al. 2021

View full text Add to dashboard Cite

Macromolecular biomolecules are currently dethroning classical small molecule therapeutics because of their improved targeting and delivery properties. Protamine-a small polycationic peptides represent a promising candidate. In nature, it binds and protects DNA against degradation during spermatogenesis due to electrostatic interactions between the negatively charged DNA-phosphate backbone and the positively charged protamine. Researchers are mimicking this technique to develop innovative nanopharmaceutical drug delivery systems, incorporating protamine as a carrier for biologically active components such as DNA or RNA. The first part of this review highlights ongoing investigations in the field of protamine-associated nanotechnology, discussing the self-assembling manufacturing process and nanoparticle engineering. Immune-modulating properties of protamine are those that lead to the second key part, which is protamine in novel vaccine technologies. Protamine-based RNA delivery systems in vaccines (some belong to the new class of mRNA-vaccines) against infectious disease and their use in cancer treatment are reviewed, and we provide an update on the current state of latest developments with protamine as pharmaceutical excipient for vaccines.

show abstract

“…For example, recent methods have been developed to generate one component-synthetic proteins with incorporated adjuvant [ 61 ]. JS7 like antigens could also be incorporated into existing vaccine platforms, such as capsid-like particles [ 62 ].…”

Section: Discussionmentioning

confidence: 99%

Synthetic proteins for COVID-19 diagnostics

et al. 2021

View full text Add to dashboard Cite

There is an urgent need for inexpensive, rapid and specific antigen-based assays to test for vaccine efficacy and detect infection with SARS-CoV-2 and its variants. We have identified a small, synthetic protein (JS7), representing a region of maximum variability within the receptor binding domain (RBD), which binds antibodies in sera from nine patients with PCR-verified COVID-19 of varying severity. Antibodies binding to either JS7 or the SARS-CoV-2 recombinant RBD, as well as those that disrupt binding between a fragment of the ACE2 receptor and the RBD, are proportional to disease severity and clinical outcome. Binding to JS7 was inhibited by linear peptides from the RBD interface with ACE2. Variants of JS7, such as E484 K or N501Y, can be quickly synthesized in a pure form in large quantities by automated methods. JS7 and related synthetic antigens can provide a basis for specific diagnostics for SARS-CoV-2 infections.

show abstract

Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

Cited by 105 publications

References 69 publications

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants

Use of Protamine in Nanopharmaceuticals—A Review

Synthetic proteins for COVID-19 diagnostics

Contact Info

Product

Resources

About